Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?

Key Points

• CPIX shares rose above their 200-day moving average, reaching $8.15 and last trading at $7.96, compared with a 200-day average of $4.87.
• Analyst sentiment remains negative: Weiss Ratings reaffirmed a “sell” rating, Wall Street Zen downgraded the stock to “hold,” and MarketBeat reports a consensus “Sell” rating.
• The company reported weaker-than-expected quarterly results, with an adjusted loss of $0.20 per share versus an expected loss of $0.13 and revenue of $0.17 million versus an $8.50 million estimate.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $4.87 and traded as high as $8.15. Cumberland Pharmaceuticals shares last traded at $7.96, with a volume of 79,334 shares traded.

Analysts Set New Price Targets

CPIX has been the subject of several analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cumberland Pharmaceuticals in a report on Wednesday, June 24th. Wall Street Zen lowered shares of Cumberland Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, May 16th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cumberland Pharmaceuticals presently has a consensus rating of "Sell".

Cumberland Pharmaceuticals Stock Performance

The firm's 50 day simple moving average is $6.55 and its 200-day simple moving average is $4.87. The company has a market capitalization of $119.24 million, a price-to-earnings ratio of -11.21 and a beta of 0.08. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.79 and a current ratio of 0.95.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last issued its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.07). Cumberland Pharmaceuticals had a negative return on equity of 26.77% and a negative net margin of 34.40%.The business had revenue of $0.17 million during the quarter, compared to analyst estimates of $8.50 million.

Cumberland Pharmaceuticals Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Friday, July 31st. Investors of record on Thursday, July 23rd were paid a $1.50 dividend.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of CPIX. XTX Topco Ltd acquired a new position in shares of Cumberland Pharmaceuticals in the 2nd quarter valued at about $34,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Cumberland Pharmaceuticals during the first quarter worth approximately $66,000. Two Sigma Investments LP boosted its holdings in shares of Cumberland Pharmaceuticals by 16.5% during the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company's stock worth $117,000 after purchasing an additional 5,326 shares during the period. Marshall Wace LLP purchased a new position in Cumberland Pharmaceuticals during the fourth quarter valued at approximately $192,000. Finally, Bank of New York Mellon Corp purchased a new position in Cumberland Pharmaceuticals during the second quarter valued at approximately $379,000. Hedge funds and other institutional investors own 15.51% of the company's stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc NASDAQ: CPIX is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland's strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company's flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source